Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Key Points • In relapsed or refractory AML, mutated NPM1 has no impact on the risk of relapse or death.• The addition of venetoclax to salvage treatment for NPM1-mutated AML is associated with improved outcomes.

[1]  J. Dipersio,et al.  Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101) , 2021, Blood.

[2]  M. Andreeff,et al.  Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.

[3]  Tamara J. Blätte,et al.  Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. , 2021, Blood.

[4]  M. Konopleva,et al.  Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. , 2020, Blood cancer discovery.

[5]  P. Fenaux,et al.  Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2020 .

[6]  J. Byrd,et al.  Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression , 2020, Clinical Cancer Research.

[7]  M. Konopleva,et al.  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. , 2020, Blood advances.

[8]  S. Saad,et al.  Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. , 2020, Blood.

[9]  S. Asthana,et al.  Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , 2019, Cancer discovery.

[10]  Tamara J. Blätte,et al.  Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation , 2019, Nature Communications.

[11]  T. Haferlach,et al.  NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. , 2018, Blood advances.

[12]  J. Jorgensen,et al.  How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? , 2017, Clinics in laboratory medicine.

[13]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[14]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[15]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[16]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[17]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[18]  H. Kantarjian,et al.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.

[19]  Uku. Innere Medizin.  Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia , 2014 .

[20]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[21]  N. Bolli,et al.  Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? , 2011, Blood.

[22]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[23]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[24]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.